The Origin Story of the Drug Crisis

Psilocybin Effective In Treating Serious Depression

Depression is often treatable with medication, therapy, or a combination of the two. But some 30% of patients don’t respond well to existing medications—and may try multiple antidepressant drugs with little or no improvement.

This week, researchers reported that a new trial suggests psychedelics may be an effective therapy for treatment-resistant depression. A randomized, controlled, double-blind trial found that people with treatment-resistant depression who were given 25 milligrams of psilocybin, the psychedelic component of magic mushrooms, had a significant decrease in depressive symptoms. The treatment didn’t work for everyone, however, and more research needs to be done before the finding can move to clinical use.

Sabrina Imber, a science fellow at the New York Times, joins Ira to talk about the trial and other stories from the week in science—including a new timeline for the planned Artemis missions to the moon, screaming bees, and a very wayward eagle.

Activists And Vulnerable Nations At COP26 Seek More Than Promises

There’s a big international climate summit wrapping up in Glasgow, Scotland this week. COP26 is the followup to 25 previous United Nations meetings about how the world must respond to the climate crisis—and its shortcomings in doing so. This year leaders had a big conversation to tackle: Countries needed to pledge to reduce emissions even further to prevent a global temperature rise of more than 1.5 degrees Celsius. To do so, they needed to finish hashing out the details of how they will enforce the 2015 Paris Agreement’s provisions.

Meanwhile, island nations and other vulnerable countries, who themselves don’t emit much carbon, have continued to lobby for payment for what’s called loss and damages. That’s the harm they’ve already encountered as seas rise, threatening to obliterate their existence.

The first week kicked off with bold pledges about methane emissions, coal phaseouts, and ending deforestation. This week, former President Obama spoke about the need for urgent action, and called out large greenhouse gas polluters like Russia and China for not attending. And a grim United Nations report was released, forecasting that despite all the bold pledges, the world was on track to warm a dangerous 2.4 degrees Celsius. The team of Threshold, a podcast that tells stories about our changing environment, has been reporting on these updates from Glasgow, talking to attendees and occasionally witnessing negotiations.

In today’s show, Ira talks to journalist Amy Martin, Threshold’s executive producer and host, about her opinion on the outcome of COP26—and if transformative change can still come out of this year’s meeting.

The opioid epidemic has affected millions of people across the country—and more than 800,000 people are estimated to have died from an opioid overdose. At the root of this crisis is the painkiller Oxycontin, manufactured by Purdue Pharma.

The company has made billions of dollars from the drug; but has also spent the better part of the last two decades fighting legal battles over its impacts, falsely arguing the drug is non-addictive and completely safe. Meanwhile, people from all walks of life, particularly in small towns across America, have been crippled by addiction to Oxycontin.

The limited series “Dopesick” traces the story of the opioid epidemic, from the creation of the Oxycontin pill to a landmark legal battle where Purdue Pharma admitted it misbranded the drug as being less addictive than other prescription opioids.

“Dopesick” follows a wide range of characters, from Purdue Pharma executives and federal prosecutors, to an Appalachian doctor and his pain-addled patients. Joining Ira to talk about bringing the show and its people to life is Danny Strong, creator and writer of “Dopesick,” joining from New York, New York.

Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.